PROVETOP

Chimeric HLA-A*02:01 (mα3) &mB2M&MAGE-A2 (KMVELVHFL) Monomer Protein

Catalog No: MAGEA2-HP001

Species
Human&Mouse
Expression System
HEK293
Tag
His

Product overview

Recombinant Chimeric HLA-A*02:01 (mα3) &mB2M&MAGE-A2 (KMVELVHFL) Monomer Protein is expressed from HEK293 with His tag at the C-terminus. It contains Gly25-Thr206 (Human HLA-A*02:01 α1&α2) and Asp207-Glu299 (Mouse H-2Ld α3), Ile21-Met119 (mB2M) and KMVELVHFL peptide (accession: A0A140T913(Human HLA-A*02:01 α1 & α2) & P01897(Mouse H-2Ld α3) & P01887(Mouse B2M) &KMVELVHFL).

Product Details

Molecular Aliases
MAGE-A2;MAGEA2
Protein Length
Gly25-Thr206
Expression System
HEK293
Theoretical Molecular Weight
The protein has a predicted MW of 48.00 kDa. Due to glycosylation, the protein migrates to 50-65 kDa based on Bis-Tris PAGE result.
Purity
> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
Endotoxin
Less than 1 EU per μg by the LAL method.
Buffer / Formulation
Supplied as 0.22 μm filtered solution in PBS (pH 7.4).
State
Liquid
Storage Conditions
Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Data Display

Bis-Tris PAGE
MAGEA2-HP001 Bis-Tris-PAGE-white result

Chimeric HLA-A*02:01 (mα3) &mB2M&MAGE-A2 (KMVELVHFL) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC
MAGEA2-HP001 SEC-HPLC result

The purity of Chimeric HLA-A*02:01 (mα3) &mB2M&MAGE-A2 (KMVELVHFL) Monomer is greater than 95% as determined by SEC-HPLC.

Background

Melanoma antigen gene (MAGE)-A2 (MAGEA2) is a member of the MAGE-A family proteins widely studied for cancer vaccine development and identification of tumor markers. MAGEA2 plays an oncogenic role in glioma progression, and they provide insight into MAGEA2 application as a novel predictor of clinical outcomes and a potential glioma biomarker.

References

  1. Meng Q, Luo G, Liu B, Sun Y, Yan Z. Melanoma-associated antigen A2 is overexpressed in glioma and associated with poor prognosis in glioma patients. Neoplasma. 2018;65(4):604-609. doi: 10.4149/neo_2018_170625N440. PMID: 30064232.

Have questions about this product?

Our technical team can help with product selection, application questions and order support.

Contact Technical Support